SCHEMBL801771

SCHEMBL801771

CCCc1cc(Nc2cnnc(-c3ccc(OC)cc3)n2)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.40
TNIK Q9UKE5 1/20 0.39
ADORA3 P0DMS8 3/20 0.39
FGFR2 P21802 5/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
GRK6 P43250 2/20 0.38
ADORA2B P29275 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
IGF1R P08069 2/20 0.37
FGFR1 P11362 2/20 0.37
KDR P35968 2/20 0.37
PLK4 O00444 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801691 0.77 ABCG2 (0.45) KDM4EGRK6AURKAAURKBIGF1R
SCHEMBL805555 0.71 ITK (0.40) GRK6CCNA2CDK2CCNA1AURKA
SCHEMBL801762 0.70 GRK6 (0.41) GRK6AURKAIGF1R
SCHEMBL13055232 0.69 CCNA2 (0.34) RETGRK6CCNA2CDK2CCNA1
SCHEMBL14005833 0.66 RET (0.47) RETADORA3AURKAAURKBKDR
SCHEMBL4159207 0.65 CCNT1 (0.48) RETTNIKAURKAAURKBPLK4
SCHEMBL27957930 0.65 MAPT (0.61) KDM4ETP53MAPTCLK4
SCHEMBL801772 0.65 ITK (0.52) RETAURKAAURKB
SCHEMBL3940505 0.64 FGFR1 (0.55) FGFR2GRK6CLK4IGF1RFGFR1
SCHEMBL13945083 0.63 RET (0.48) RETAURKAAURKBKDRPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed
US-7691853-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A RET 319/4885TNIK 341/4885ADORA3 821/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 RET 207/4885TNIK 500/4885ADORA3 406/4885
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors GSK3B, CDK3, GSK3A RET 319/4885TNIK 341/4885ADORA3 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.